Please assess the completion status of the following clinical trial:

Trial Title: Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NASH on liver biopsy (within 6 months of screening visit).~* NAFLD Activity Score (NAS) ≥ 3, comprising of a minimum of 1 point from each of the individual steatosis, lobular inflammation and hepatocyte ballooning scores~* Body Mass Index (BMI) ≥ 25 at randomisation~* Type 2 Diabetes Mellitus/impaired glucose tolerance or normal glucose tolerance~Exclusion Criteria (brief):~* Insulin dependent diabetes~* Glycosylated Haemoglobin (HbA1c) \> 9.0%~* treatment with dipeptidyl peptidase 4 (DPP-IV) inhibitors, Glucagon-like Peptides (GLP) 1 analogues, thiazolidinediones (TZDs)~* Past Medical History of Acute (or chronic) pancreatitis/pancreatic carcinoma, weight loss surgery, liver transplantation, Medullary thyroid cancer, hepatocellular carcinoma (HCC), Multiple Endocrine Neoplasia (MEN) syndrome, malignancy (within last 3 years, exception of treated skin malignancy)~* Other liver aetiologies (i.e. drug-induced, viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, haemochromatosis, alpha 1 anti-trypsin deficiency, Wilsons disease)~* concomitant or recent use of orlistat, prednisolone,~* Refusal or lacks capacity to give informed consent to participate in the trial~* Participation in any clinical trial of an investigational therapy or agent within 3 months of randomisation~* Patient (or carer) deemed not competent at using the correct site and technique for subcutaneous injection of the trial treatment (containing dummy drug on practice) at visit 2~* NAS\<3~* Child's B or C cirrhosis~* Abnormal clinical examination of thyroid (i.e. unexplained goitre or palpable nodules)~* Liver enzymes \> 10 x upper limit of normal~* Average alcohol consumption per week \> 21 units (210g) male, \>14 units (140g) female within the last 5 years.~* \>5% weight loss since the diagnostic liver biopsy was obtained.~* Recent or concomitant use of steroids (oral), methotrexate, amiodarone, Orlistat~* Addition or significant change (as judged by the chief investigator) in dose of the following drugs; Angiotensin converting enzymes (ACE)-inhibitors, Angiotensin receptor blockers (ARBs) and/or Multi-vitamins (containing Vitamin E)~* Known positivity for antibody to Human Immunodeficiency virus (HIV)~* Serum creatinine \> 150 μmol/L or currently being treated with renal replacement therapy~* Past medical history of multiple drug allergies (defined as anaphylactoid drug reactions in \>2 drug groups)~* Presence of any acute/chronic infections or illness that at the discretion of the chief investigator might compromise the patient's health and safety in the trial~* Pregnancy or breastfeeding~* Women, of child-bearing age, who are not willing to practise effective contraception (i.e. barrier, oral contraceptive pill, implanon or history hysterectomy) for the 48 week duration of the trial and for one-month after the last administration of the drug.~* Men, sexually active with women of child-bearing age, who are not willing to practise effective contraception for the 48 week duration of the trial and for one-month after the last administration of the drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
- Placebo (Type: PLACEBO_COMPARATOR): Liraglutide-Placebo manufactured by Novo Nordisk.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete